All News
Filter News
Found 808,541 articles
-
AVEO Oncology to Regain Ex-North American Rights to AV-203
3/15/2021
AVEO Oncology to Regain Ex-North American Rights to AV-203 - AVEO Pipeline to Include Global Rights to Three Clinical-Stage and One Commercial-Stage Assets, Including Ficlatuzumab and AV-380 -
-
Intec Pharma and Decoy Biosystems Announce Merger Agreement
3/15/2021
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") announced today that it has entered into a definitive agreement for a business combination with Decoy Biosystems, Inc., a privately-held, preclinical-stage biotechnology company developing novel, multi-targeted products that safely prime both innate and adaptive anti-tumor and anti-viral immune responses.
-
CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating that Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative Disease
3/15/2021
CuraSen Therapeutics, Inc., a privately held, clinical-stage biotechnology company, announced Phase 1 proof-of-principle data demonstrating that salbutamol, a drug approved to treat respiratory disease, significantly improved brain perfusion as measured by increased cerebral blood flow (CBF) in healthy subjects.
-
INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
3/15/2021
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as Executive Vice President and General Counsel.
-
Newron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide in Parkinson’s Disease Patients
3/15/2021
Newron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide in Parkinson’s Disease Patients Global study to evaluate the reduction of levodopa-induced dyskinesia (PD LID) Targeting safinamide label extension for PD LID in key global markets
-
Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
3/15/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference
-
New IPVM Scientific Study Raises Alarm on COVID-19 Temperature Screening Reporting Fevers as Normal
3/15/2021
A new peer-reviewed study by IPVM researchers has found that popular temperature screening devices from 7 different manufacturers systematically manipulate temperature readings, regularly reporting fever-level temperatures as normal.
-
Lygos and the Agile BioFoundry Generate Largest Multi-Omics Dataset to Accelerate Machine Learning Capabilities for Engineering Strains for Producing Organic Acids
3/15/2021
Lygos, Inc., a vertically integrated provider of safe and sustainable specialty ingredients, today announced that it is working with the U.S. Department of Energy Bioenergy Technologies Office’s Agile BioFoundry (ABF) to generate the largest multi-omics dataset for guiding the development of organic acids.
-
Seisa Medical Establishes California Presence With Acquisitions of ProtoQuick and Peridot
3/15/2021
Seisa Medical Inc., a full-service provider of integrated manufacturing and development services to the medical device industry, today announced that it has acquired Bay Area-based businesses ProtoQuick, Inc. and Peridot Corporation.
-
Centene Announces Expiration of Hart-Scott-Rodino Waiting Period with Respect to the Company's Proposed Acquisition of Magellan Health Inc.
3/15/2021
Centene Corporation (NYSE: CNC) has announced that as of 11:59 p.m. on March 12th, 2021, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the Company's proposed acquisition of Magellan Health Inc. has expired.
-
ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing
3/15/2021
- Proceeds to support the acceleration and scaling of ElevateBio’s end-to-end cell and gene therapy technology platform offering - Series C financing led by Matrix Capital Management, joined by additional new investors SoftBank Vision Fund 2 and Fidelity Management & Research Company alongside ElevateBio’s existing investors
-
Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis
3/15/2021
Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate, today announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited
-
Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.
3/15/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”).
-
LAVA Therapeutics B.V. Appoints Edward F. Smith as Chief Financial Officer
3/15/2021
LAVA Therapeutics B.V. (“LAVA”, or the “Company”), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced that it is expanding its management team with the appointment of Edward F. Smith as its chief financial officer.
-
Data from STEP clinical trial program evaluating effect of semaglutide 2.4 mg in people with obesity to be presented at 2021 ENDO annual meeting
3/15/2021
Novo Nordisk today announced that results from three trials from the pivotal STEP (Semaglutide Treatment Effect in People with obesity) phase 3 clinical development program with investigational once-weekly subcutaneous semaglutide 2.4 mg will be shared at the virtual ENDO Annual Meeting on March 20-23.
-
Ardelyx Appoints Muna Bhanji, R.Ph, to its Board of Directors
3/15/2021
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced the appointment of Muna Bhanji, R.Ph, to the company's board of directors, effective March 11, 2021.
-
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
3/15/2021
– Collaboration to Focus on Oral and Injectable Formulations of Lenacapavir and Islatravir – – Agreement Brings Together Potentially Complementary Medicines in Late-Stage Development with the Goal to Provide Innovative, Long-Acting Treatments in HIV –
-
Veracyte Completes Acquisition of Decipher Biosciences
3/15/2021
Veracyte, Inc. (Nasdaq: VCYT) today announced it has completed its acquisition of Decipher Biosciences, Inc. to further solidify its global leadership in genomic diagnostics, with an expanded reach into 7 of the 10 most common cancers in the United States, while accelerating revenue growth.
-
Stoicheia Announces Scientific Advisory Board
3/15/2021
Stoicheia, a new technology startup that uses a nanotechnology-based approach to ultrahigh throughput materials discovery, today announced the first four members of its scientific advisory board.
-
Taconic Biosciences Expands Scientific Advisory BoardDr. Monica Gostissa Joins Taconic Biosciences’ Scientific Advisory Board
3/15/2021
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces Monica Gostissa, PhD, has joined its Scientific Advisory Board (SAB). Dr. Gostissa joins existing board members, Frank Sistare, PhD; Andrew Goodman, PhD; David Hill, PhD; and Robert Rosenthal, PhD.